1. Schwartz PJ, Priori SG. Long QT syndrome: genotype-phenotype correlations. In: Zipes DP, Jalife J, editors. Cardiac
Electrophysiology: From Cell to Bedside, 4th ed. WB Saunders Co, 2004: 651–659.
2. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392:
293-296.
3. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957; 54: 59-68.
4. Romano C, Gemme G, Pongiglione R. Rare cardiac arrhythmias of the pediatric age II. Syncopal attacks due to paroxysmal ventricular fibrillation. (Presentation of 1st case in Italian pediatric literature).
Clin Pediatr (Bologna) 1963; 45: 656-683 (in Italian).
5. Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc 1964; 54: 103-106.
6. Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation 2006; 113: 783-790.
7. Itoh H, Sakaguchi T, Ding WG, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol 2009; 2: 511-523.
8. Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen's syndrome:
potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994; 35: 326-330.
9. Plaster NM, Tawil R, Tristani-Firouzi M, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001; 105: 511-519.
10. Ai T, Fujiwara Y, Tsuji K, et al. Novel KCNJ2 mutation in familial periodic paralysis with ventricular dysrhythmia. Circulation 2002;
105: 2592-2594.
11. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythmia Electrophysiol 2012; 5: 868-877.
12. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348: 1866-1874.
13. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011; 57: 51-59.
14. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009; 120: 1761-1767.
15. Itoh H, Shimizu W, Hayashi K, et al. Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multicenter study. Heart Rhythm 2010; 7: 1411-1418.
16. Schwartz PJ, Stramba-Badiale M, Segantini A, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998; 338: 1709-1714.
17. Schwartz PJ, Priori SG, Dumaine R, et al. A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med 2000; 343: 262-267.
18. Schwartz PJ, Priori SG, Bloise R, et al. Molecular diagnosis in a child with sudden infant death syndrome. Lancet 2001; 358: 1342-1343.
19. Arnestad M, Crotti L, Rognum TO, et al. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation 2007; 115: 361-367.
20. Priori SG, Maugeri FS, Schwartz PJ. The risk of sudden death as first cardiac event in asymptomatic patients with the long QT syndrome (abstract). Circulation 1998; 98: 777.
21. Morganroth J, Horowitz LN. Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias. Am J Cardiol 1985; 56: 585-587.
22. Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990; 65:
74A-81A; discussion 82A-83A.
23. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs:
clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47:
219-233.
24. Kurita T, Ohe T, Marui N, et al. Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsades de pointes. Am J Cardiol 1992; 69: 628-633.
25. Oka Y, Itoh H, Ding WG, et al. Atrioventricular block-induced Torsades de Pointes with clinical and molecular backgrounds similar to congenital long QT syndrome. Circ J 2010; 74: 2562-2571.
26. Litwin JS, Kleiman RB, Gussak I. Acquired (drug-induced) long QT syndrome. In: Gussak I, Antzelevitch C, editors. Electrical diseases of the heart. Springer-Verlag, 2008: 705-718.
27. Andreoli A, di Pasquale G, Pinelli G, et al. Subarachnoid
hemorrhage: frequency and severity of cardiac arrhythmias. A survey of 70 cases studied in the acute phase. Stroke 1987; 18: 558-564.
28. Mitcheson JS, Chen J, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000; 97:
12329-12333.
29. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
30. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest 2005; 115: 2025-2032.
31. Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002; 106: 1269-1274.
32. Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997;
96: 2778-2781.
33. Kubota T, Shimizu W, Kamakura S, et al. Hypokalemia-induced long QT syndrome with an underlying novel missense mutation in S4-S5 linker of KCNQ1. J Cardiovasc Electrophysiol 2000; 11: 1048-1054.
34. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11:
691-696.
35. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000; 97: 10613-10618.
36. Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) 2004; 82: 182-188.
37. Shimizu W. Clinical impact of genetic studies in lethal inherited cardiac arrhythmias. Circ J 2008; 72: 1926-1936.
38. Shimizu W, Horie M. Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels. Circ Res 2011; 109: 97-109.
39. Ohe T, Kurita T, Aihara N, et al. Electrocardiographic and electrophysiologic studies in patients with torsades de pointes--role of monophasic action potentials. Jpn Circ J 1990; 54: 1323-1330.
40. Shimizu W, Ohe T, Kurita T, et al. Early afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome.
Circulation 1991; 84: 1915-1923.
41. Shimizu W, Ohe T, Kurita T, et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 1995; 26: 1299-1309.
42. Shimizu W, Kurita T, Matsuo K, et al. Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long-QT syndrome. Circulation 1998; 97: 1581-1588.
43. Kurita T, Ohe T, Shimizu W, et al. Early afterdepolarization like activity in patients with class IA induced long QT syndrome and torsades de pointes. Pacing Clin Electrophysiol 1997; 20: 695-705.
44. Franz MR. Long-term recording of monophasic action potentials from human endocardium. Am J Cardiol 1983; 51: 1629-1634.
45. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997; 96: 2038-2047.
46. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: Effects of β-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998;
98: 2314-2322.
47. Shimizu W, Antzelevitch C. Effects of a K+ channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome.
Circulation 2000; 102: 706-712.
48. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome.
Circulation 1995; 92: 2929-2934.
49. Aiba T, Shimizu W, Inagaki M, et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
J Am Coll Cardiol 2005; 45: 300-307.
50. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20: 1391-1396.
51. Miyasaka Y, Tsuji H, Yamada K, et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol 2001; 38: 771-774.
52. Matsuo K, Akahoshi M, Nakashima E, et al. The prevalence, incidence and prognostic value of the Brugada-type
electrocardiogram: a population-based study of four decades. J Am Coll Cardiol 2001; 38: 765-770.
53. Furuhashi M, Uno K, Tsuchihashi K, et al. Prevalence of asymptomatic ST segment elevation in right precordial leads with right bundle branch block (Brugada-type ST shift) among the general Japanese population. Heart 2001; 86: 161-166.
54. Atarashi H, Ogawa S, Harumi K, et al. Three-year follow-up of patients with right bundle branch block and ST segment elevation in the right precordial leads: Japanese Registry of Brugada Syndrome.
Idiopathic Ventricular Fibrillation Investigators. J Am Coll Cardiol 2001; 37: 1916-1920.
55. 戸兵雄子, 中沢潔, 小沢敦, 他. 右脚ブロックパターンとST上昇型 心電図の疫学. 心電図 1995; 15: 223-226.
56. Sakabe M, Fujiki A, Tani M, et al. Proportion and prognosis of healthy people with coved or saddle-back type ST segment elevation in the right precordial leads during 10 years follow-up. Eur Heart J 2003; 24: 1488-1493.
57. Yamakawa Y, Ishikawa T, Uchino K, et al. Prevalence of right bundle-branch block and right precordial ST-segment elevation (Brugada-type electrocardiogram) in Japanese children. Circ J 2004;
68: 275-279.
58. Ohe H, Takagi M, Tanaka A, et al. Prevalence and clinical course of the juveniles with Brugada-type ECG in Japanese population. Pacing Clin Electrophysiol 2005; 28: 549-554.
59. Brugada J, Brugada R, Antzelevitch C, et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3.
Circulation 2002; 105: 73-78.
60. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108:
3092-3096.
61. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management.
Circulation 2002; 105: 1342-1347.
62. Eckardt L, Probst V, Smits JP, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 2005; 111: 257-263.
63. Giustetto C, Drago S, Demarchi PG, et al. Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study. Europace 2009; 11: 507-513.
64. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada syndrome registry. Circulation 2010; 121:
635-643.
65. Takagi M, Yokoyama Y, Aonuma K, et al; Japan idiopathic ventricular fibrillation study (J-IVFS) investigators. Clinical characteristics and risk stratification in symptomatic and
asymptomatic patients with Brugada syndrome: multicenter study in Japan. J Cardiovasc Electrophysiol 2007; 18: 1244-1251.
66. Kamakura S, Ohe T, Nakazawa K, et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. Circ Arrhythm Electrophysiol 2009; 2: 495-503.
67. Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002; 106: 2004-2011.
68. Shimizu W, Matsuo K, Kokubo Y, et al. Sex hormone and gender difference--role of testosterone on male predominance in Brugada syndrome. J Cardiovasc Electrophysiol 2007; 18: 415-421.
69. Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men.
Circulation 1997; 96: 2595-2600.
70. 元木賢三, 辻村武文. いわゆる ぽっくり 病からの生還例と思わ
れる１例. 心臓 1990; 22: 1221-1226.
71. Bezzina CR, Shimizu W, Yang P, et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac
conduction. Circulation 2006; 113: 338-344.
72. Champagne J, Philippon F, Gilbert M, et al. The Brugada syndrome in Canada: a unique French-Canadian experience. Can J Cardiol 2007; 23 Suppl B: 71B-75B.
73. Ouali S, Boughzela E, Haggui A, et al. Clinical and
electrophysiological profile of Brugada syndrome in the Tunisian population. Pacing Clin Electrophysiol 2011; 34: 47-53.
74. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome:
report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association.
Circulation 2005; 111: 659-670.
75. Takigawa M, Noda T, Shimizu W, et al. Seasonal and circadian distributions of ventricular fibrillation in patients with Brugada syndrome. Heart Rhythm 2008; 5: 1523-1527.
76. Morita H, Nagase S, Miura D, et al. Differential effects of cardiac sodium channel mutations on initiation of ventricular arrhythmias in patients with Brugada syndrome. Heart Rhythm 2009; 6: 487-492.
77. Kusano KF, Taniyama M, Nakamura K, et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol 2008; 51: 1169-1175.
78. Noda T, Shimizu W, Taguchi A, et al. ST-segment elevation and ventricular fibrillation without coronary spasm by intracoronary injection of acetylcholine and/or ergonovine maleate in patients with Brugada syndrome. J Am Coll Cardiol 2002; 40: 1841-1847.
79. Yokokawa M, Okamura H, Noda T, et al. Neurally mediated syncope as a cause of syncope in patients with Brugada electrocardiogram. J Cardiovasc Electrophysiol 2010; 21: 186-192.
80. Junttila MJ, Gonzalez M, Lizotte E, et al. Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias.
Circulation 2008; 117: 1890-1893.
81. Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation 2008; 118: 1697-1704.
82. Makimoto H, Nakagawa E, Takaki H, et al. Augmented ST-segment elevation during recovery from exercise predicts cardiac events in patients with Brugada syndrome. J Am Coll Cardiol 2010; 56:
1576-1584.
83. Makimoto H, Kamakura S, Aihara N, et al. Clinical impact of the number of extrastimuli in programmed electrical stimulation in patients with Brugada type 1 electrocardiogram. Heart Rhythm 2012;
9: 242-248.
84. Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002; 106: 2514-2519.
85. Bezzina CR, Rook MB, Wilde AA. Cardiac sodium channel and inherited arrhythmia syndromes. Cardiovasc Res 2001; 49: 257-271.
86. Grant AO, Carboni MP, Neplioueva V, et al. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest 2002; 110: 1201-1209.
87. Morita H, Zipes DP, Wu J. Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratification from experimental observations. Heart Rhythm 2009; 6: S34-43.
88. Balser JR. The cardiac sodium channel: gating function and molecular pharmacology. J Mol Cell Cardiol 2001; 33: 599-613.
89. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001; 12: 268-272.
90. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999; 100: 1660-1666.
91. Take Y, Morita H, Wu J, et al. Spontaneous electrocardiogram alterations predict ventricular fibrillation in Brugada syndrome. Heart Rhythm 2011; 8: 1014-1021.
92. Miyazaki T, Mitamura H, Miyoshi S, et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996; 27: 1061-1070.
93. Vernooy K, Delhaas T, Cremer OL, et al. Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm 2006; 3: 131-137.
94. Nishizaki M, Sakurada H, Ashikaga T, et al. Effects of glucose-induced insulin secretion on ST segment elevation in the Brugada syndrome. J Cardiovasc Electrophysiol 2003; 14: 243-249.
95. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43: 1853-1860.
96. Mizusawa Y, Sakurada H, Nishizaki M, et al. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment. J Cardiovasc Pharmacol 2006; 47: 359-364.
97. Kurita T, Shimizu W, Inagaki M, et al. The electrophysiologic
mechanism of ST-segment elevation in Brugada syndrome. J Am Coll Cardiol 2002; 40: 330-334.
98. Aiba T, Shimizu W, Hidaka I, et al. Cellular basis for trigger and maintenance of ventricular fibrillation in the Brugada syndrome model: high-resolution optical mapping study. J Am Coll Cardiol 2006; 47: 2074-2085.
99. Ikeda T, Sakurada H, Sakabe K, et al. Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome:
insight into risk stratification. J Am Coll Cardiol 2001; 37: 1628-1634.
100. Nagase S, Kusano KF, Morita H, et al. Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome:
using the epicardial lead. J Am Coll Cardiol 2002; 39: 1992-1995.
101. Tukkie R, Sogaard P, Vleugels J, et al. Delay in right ventricular activation contributes to Brugada syndrome. Circulation 2004; 109:
1272-1277.
102. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? Cardiovasc Res 2005; 67: 367-378.
103. Doi A, Takagi M, Maeda K, et al. Conduction delay in right ventricle as a marker for identifying high-risk patients with Brugada syndrome.
J Cardiovasc Electrophysiol 2010; 21: 688-696.
104. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium.
Circulation 2011; 123: 1270-1279.
105. Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently normal heart. Cardiovasc Res 2001; 50:
399-408.
106. Coronel R, Casini S, Koopmann TT, et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 2005; 112: 2769-2777.
107. Schwartz PJ. Idiopathic long QT syndrome: progress and questions.
Am Heart J 1985; 109: 399-411.
108. Wilde AA, Jongbloed RJ, Doevendans PA, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 1999; 33: 327-332.
109. Shimizu W, Horie M, Ohno S, et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome:
multicenter study in Japan. J Am Coll Cardiol 2004; 44: 117-125.
110. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89-95.
111. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002; 105: 794-799.
112. Hofman N, Wilde AA, Kaab S, et al. Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: do we need a scoring system? Eur Heart J 2007; 28: 575-580.
113. Moss AJ, Robinson JL, Gessman L, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999; 84: 876-879.
114. Moss AJ, Shimizu W, Wilde AA, et al. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007; 115:
2481-2489.
115. Shimizu W, Moss AJ, Wilde AA, et al. Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol 2009; 54: 2052-2062.
116. 吉永正夫. 胎児期, 小児期の遺伝性不整脈における問題点とその対 策. 医のあゆみ 2006; 217: 669-674.
117. Hamada H, Horigome H, Asaka M, et al. Prenatal diagnosis of long QT syndrome using fetal magnetocardiography. Prenat Diagn 1999;
19: 677-680.
118. Hoorntje T, Alders M, van Tintelen P, et al. Homozygous premature truncation of the HERG protein : the human HERG knockout.
Circulation 1999; 100: 1264-1267.
119. Miura M, Yamagishi H, Morikawa Y, et al. Congenital long QT syndrome and 2: 1 atrioventricular block with a mutation of the SCN5A gene. Pediatr Cardiol 2003; 24: 70-72.
120. Gorgels AP, Al Fadley F, Zaman L, et al. The long QT syndrome with impaired atrioventricular conduction: a malignant variant in infants. J Cardiovasc Electrophysiol 1998; 9: 1225-1232.
120a. Horigome H, Nagashima M, Sumitomo N, et al. Clinical
characteristics and genetic background of congenital long-QT syndrome diagnosed in fetal, neonatal, and infantile life: a nationwide questionnaire survey in Japan. Circ Arrhythm Electrophysiol 2010; 3:
10-17.
121. Schmitz L, Burghoff M. Images in cardiovascular medicine.
Magnetocardiography in a fetus with long-QT syndrome. Circulation 2005; 112: e68-69.
122. Miller TE, Estrella E, Myerburg RJ, et al. Recurrent third-trimester fetal loss and maternal mosaicism for long-QT syndrome. Circulation 2004; 109: 3029-3034.
123. Ackerman MJ, Siu BL, Sturner WQ, et al. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA 2001; 286: 2264-2269.
124. Christiansen M, Tonder N, Larsen LA, et al. Mutations in the HERG K+-ion channel: a novel link between long QT syndrome and sudden infant death syndrome. Am J Cardiol 2005; 95: 433-434.
125. Cronk LB, Ye B, Kaku T, et al. Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm 2007; 4: 161-166.
126. Tan BH, Pundi KN, Van Norstrand DW, et al. Sudden infant death syndrome-associated mutations in the sodium channel beta subunits.
Heart Rhythm 2010; 7: 771-778.
127. Cheng J, Van Norstrand DW, Medeiros-Domingo A, et al. Alpha1-syntrophin mutations identified in sudden infant death syndrome cause an increase in late cardiac sodium current. Circ Arrhythm Electrophysiol 2009; 2: 667-676.
128. Otagiri T, Kijima K, Osawa M, et al. Cardiac ion channel gene mutations in sudden infant death syndrome. Pediatr Res 2008; 64:
482-487.
129. Shim SH, Ito M, Maher T, et al. Gene sequencing in neonates and infants with the long QT syndrome. Genet Test 2005; 9: 281-284.
130. Tanaka Y, Yoshinaga M, Anan R, et al. Usefulness and cost effectiveness of cardiovascular screening of young adolescents. Med Sci Sports Exerc 2006; 38: 2-6.
131. Zupancic JA, Triedman JK, Alexander M, et al. Cost-effectiveness and implications of newborn screening for prolongation of QT interval for the prevention of sudden infant death syndrome. J Pediatr 2000; 136: 481-489.
132. Fukushige T, Yoshinaga M, Shimago A, et al. Effect of age and overweight on the QT interval and the prevalence of long QT syndrome in children. Am J Cardiol 2002; 89: 395-398.
133. Yoshinaga M, Nagashima M, Shibata T, et al. Who is at risk for cardiac events in young patients with long QT syndrome? Circ J 2003; 67: 1007-1012.
134. 吉永正夫, 新村一郎, 長嶋正實, 他. QT延長症候群患児の管理基準 に関する研究委員会報告. 日小児循環器会誌 2004; 20: 52-53.
135. Moss AJ. Long QT Syndrome. JAMA 2003; 289: 2041-2044.
136. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death.
Nature 2003; 421: 634-639.
137. Lupoglazoff JM, Denjoy I, Berthet M, et al. Notched T waves on Holter recordings enhance detection of patients with LQt2 (HERG) mutations. Circulation 2001; 103: 1095-1101.
138. Surawicz B. Will QT dispersion play a role in clinical decision-making? J Cardiovasc Electrophysiol 1996; 7: 777-784.
139. Batchvarov V, Malik M. Measurement and interpretation of QT dispersion. Prog Cardiovasc Dis 2000; 42: 325-344.
140. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000; 102:
2849-2855.
141. Priori SG, Mortara DW, Napolitano C, et al. Evaluation of the spatial aspects of T-wave complexity in the long-QT syndrome. Circulation 1997; 96: 3006-3012.
142. Kanters JK, Fanoe S, Larsen LA, et al. T wave morphology analysis distinguishes between KvLQT1 and HERG mutations in long QT syndrome. Heart Rhythm 2004; 1: 285-292.
143. Vaglio M, Couderc JP, McNitt S, et al. A quantitative assessment of T-wave morphology in LQT1, LQT2, and healthy individuals based on Holter recording technology. Heart Rhythm 2008; 5: 11-18.
144. Tan HL, Hofman N, van Langen IM, et al. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation 2005; 112: 207-213.
145. Novotny T, Sisakova M, Kadlecova J, et al. Occurrence of notched T wave in healthy family members with the long QT interval syndrome.
Am J Cardiol 2004; 94: 808-811.
146. Kaltman JR, Ro PS, Stephens P, et al. Effects of beta-adrenergic antagonists on the QT measurements from exercise stress tests in pediatric patients with long QT syndrome. Pediatr Cardiol 2003; 24: